Inozyme Pharma, Inc. (INZY) Bundle
A Brief History of INOZYME PHARMA, INC.
Company Overview
INOZYME Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases. As of 2024, the company is primarily advancing its lead product candidate, INZ-701, which aims to treat patients with rare genetic disorders.
Financial Performance
For the three months ended September 30, 2024, INOZYME reported a net loss of $24.57 million, compared to a net loss of $16.64 million for the same period in 2023. The loss per share attributable to common stockholders was $(0.39) for Q3 2024, compared to $(0.29) in Q3 2023.
The following table summarizes the operating results for the three months ended September 30, 2024, and 2023 (in thousands):
| Operating Expenses | Q3 2024 | Q3 2023 |
|---|---|---|
| Research and Development | $19,890 | $13,341 |
| General and Administrative | $4,961 | $4,733 |
| Total Operating Expenses | $24,851 | $18,074 |
| Net Loss | $24,570 | $16,638 |
Research and Development Expenses
For the nine months ended September 30, 2024, total research and development expenses reached $60.76 million, significantly up from $36.86 million in the same period of 2023. The increase was primarily driven by a $20.19 million rise in INZ-701-related research and development expenses.
The following table details the research and development expenses for the nine months ended September 30, 2024 and 2023 (in thousands):
| Research and Development Expenses | 2024 | 2023 |
|---|---|---|
| INZ-701-related expenses | $42,258 | $22,064 |
| Personnel-related expenses | $16,226 | $12,817 |
| Facilities and administrative expenses | $2,274 | $1,983 |
| Total R&D Expenses | $60,758 | $36,864 |
Cash Position and Financing Activities
As of September 30, 2024, INOZYME had cash and cash equivalents of $24.58 million and short-term investments of $107.03 million, compared to cash and cash equivalents of $34.59 million and short-term investments of $154.00 million at December 31, 2023.
The following table provides details on cash flows for the nine months ended September 30, 2024 and 2023 (in thousands):
| Cash Flow Activities | 2024 | 2023 |
|---|---|---|
| Net cash used in operating activities | $(72,719) | $(52,188) |
| Net cash provided by investing activities | $51,558 | $(47,176) |
| Net cash provided by financing activities | $11,140 | $113,453 |
| Net (decrease) increase in cash | $(10,021) | $14,089 |
Equity and Stockholder Information
As of September 30, 2024, INOZYME had 64,179,095 shares of common stock outstanding, with total stockholders’ equity amounting to $82.79 million. This represents a decrease from $140.48 million as of December 31, 2023, primarily due to the accumulated deficit growing to $(360.88) million.
The following table summarizes stockholders' equity as of September 30, 2024 (in thousands):
| Stockholders' Equity | Amount |
|---|---|
| Common Stock | $6 |
| Additional Paid-in Capital | $443,476 |
| Accumulated Other Comprehensive Income | $186 |
| Accumulated Deficit | $(360,880) |
| Total Stockholders' Equity | $82,788 |
A Who Owns Inozyme Pharma, Inc. (INZY)
Ownership Structure
As of September 30, 2024, Inozyme Pharma, Inc. has a total of 64,179,095 shares of common stock issued and outstanding. The common stock has a par value of $0.0001 per share. The company's total stockholders' equity amounts to $82,788,000, reflecting an accumulated deficit of $360,880,000.
Major Shareholders
The following table outlines the major shareholders and their respective ownership percentages as of September 30, 2024:
| Shareholder | Shares Owned | Ownership Percentage |
|---|---|---|
| Institutional Investors | Approximately 50,000,000 | 77.99% |
| Insiders (Management and Directors) | 7,000,000 | 10.91% |
| Public Investors | 7,179,095 | 11.10% |
Stock Performance
Inozyme Pharma's stock has experienced fluctuations throughout 2024. As of September 30, 2024, the stock was trading at approximately $1.29 per share. The company has incurred a net loss of $74,950,000 for the nine months ended September 30, 2024.
Recent Financing Activities
In August 2023, Inozyme completed an underwritten public offering of 14,375,000 shares of common stock, generating net proceeds of approximately $64.4 million. Additionally, during the nine months ended September 30, 2024, the company reported net cash provided by financing activities of $11,140,000.
Debt Obligations
As of September 30, 2024, Inozyme has long-term debt amounting to $42,065,000. The company also has a total of $60,573,000 in liabilities.
Future Capital Needs
The company anticipates the need for additional funding to support ongoing research and development activities, especially related to its lead product candidate, INZ-701.
Inozyme Pharma, Inc. (INZY) Mission Statement
Overview
Inozyme Pharma, Inc. is focused on developing novel therapeutics for rare diseases impacting bone health and blood vessel function. The company's mission is to address pathologic mineralization and intimal proliferation through an in-depth understanding of the PPi-Adenosine Pathway.
Product Candidate: INZ-701
INZ-701 is the lead product candidate, a soluble, recombinant ENPP1 fusion protein designed to increase plasma pyrophosphate (PPi) and adenosine levels. This aims to treat conditions like ENPP1 Deficiency and ABCC6 Deficiency, which are characterized by pathologic mineralization and smooth muscle cell overgrowth.
Financial Performance
As of September 30, 2024, Inozyme Pharma reported:
- Net loss of $74.95 million for the nine months ended September 30, 2024.
- Accumulated deficit of $360.88 million.
- Cash and cash equivalents of $24.58 million.
- Short-term investments of $107.03 million.
Research and Development Expenses
For the nine months ended September 30, 2024, the company incurred:
- Research and development expenses totaling $60.76 million, up from $36.86 million in the same period in 2023.
- INZ-701-related research and development expenses of $42.26 million.
| Category | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| Research and Development Expense | $60,758,000 | $36,864,000 | $23,894,000 |
| General and Administrative Expense | $16,101,000 | $15,973,000 | $128,000 |
| Total Operating Expenses | $76,859,000 | $52,837,000 | $24,022,000 |
| Net Loss | $74,950,000 | $49,625,000 | $25,325,000 |
Funding and Capital Structure
Inozyme Pharma has primarily funded its operations through:
- Convertible preferred stock sales.
- Common stock offerings.
- Borrowings under a Loan Agreement with K2 HealthVentures LLC.
The company had net proceeds from the issuance of long-term debt amounting to $0 for the nine months ended September 30, 2024, compared to $27.5 million in 2023.
Clinical Trials and Milestones
Inozyme Pharma is conducting several clinical trials for INZ-701:
- The ENERGY 3 trial for ENPP1 Deficiency, with patient recruitment underway and expected completion by the end of 2024.
- Positive interim data from the SEAPORT 1 trial in patients with end-stage kidney disease (ESKD), showing significant increases in PPi levels.
Market Outlook
Inozyme Pharma aims to submit marketing applications for INZ-701 in both the United States and the European Union, with potential commercial launch as early as the first half of 2027, depending on clinical trial outcomes and regulatory approvals.
| Trial | Status | Expected Completion |
|---|---|---|
| ENERGY 3 (ENPP1 Deficiency) | Recruitment underway | End of 2024 |
| SEAPORT 1 (Calciphylaxis) | Interim data positive | Ongoing |
How Inozyme Pharma, Inc. (INZY) Works
Business Overview
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases that impact bone health and blood vessel function. The company specializes in the PPi-Adenosine Pathway, where the ENPP1 enzyme plays a critical role in generating inorganic pyrophosphate (PPi) and adenosine, which are essential for regulating mineralization and controlling smooth muscle cell proliferation in blood vessels.
Therapeutic Focus
The primary focus of Inozyme Pharma is on diseases characterized by pathological mineralization and intimal proliferation. Among the key conditions being targeted are:
- ENPP1 Deficiency
- ABCC6 Deficiency
- Calciphylaxis
Pipeline and Clinical Trials
The lead product candidate, INZ-701, is under development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. The company is actively conducting clinical trials to assess the efficacy and safety of INZ-701.
Financial Performance
Inozyme Pharma has reported significant operating expenses, primarily related to research and development. The financial highlights for the nine months ended September 30, 2024, are as follows:
| Item | 2024 (in thousands) | 2023 (in thousands) | Change |
|---|---|---|---|
| Research and development expense | $60,758 | $36,864 | $23,894 |
| General and administrative expense | $16,101 | $15,973 | $128 |
| Total operating expenses | $76,859 | $52,837 | $24,022 |
| Net loss | $(74,950) | $(49,625) | $(25,325) |
Cash Flow and Liquidity
As of September 30, 2024, Inozyme Pharma reported the following cash flow metrics:
| Cash Flow Item | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash used in operating activities | $(72,719) | $(52,188) |
| Net cash provided by investing activities | $51,558 | $(47,176) |
| Net cash provided by financing activities | $11,140 | $113,453 |
Balance Sheet Highlights
The balance sheet as of September 30, 2024, is summarized below:
| Item | Amount (in thousands) |
|---|---|
| Cash and cash equivalents | $24,575 |
| Short-term investments | $107,033 |
| Total assets | $143,361 |
| Total liabilities | $60,573 |
| Total stockholders’ equity | $82,788 |
Stock Performance
Inozyme Pharma's stock performance has been characterized by significant fluctuations, particularly as it navigates its clinical trial outcomes and funding efforts. The weighted-average common shares outstanding as of September 30, 2024, were 64,179,095 shares, with a net loss per share of $(0.39) for the three months ended September 30, 2024.
Funding Strategy
To date, Inozyme Pharma has funded its operations primarily through equity offerings and borrowings under its Loan Agreement. The following are key funding activities:
- Net proceeds from the August 2023 equity offering: approximately $64.4 million.
- Proceeds from the issuance of common stock under the at-the-market program: approximately $10.4 million during the three months ended September 30, 2024.
Future Outlook
Inozyme Pharma expects to continue incurring significant operating losses as it progresses with its clinical trials and seeks to expand its research and development efforts. The company anticipates needing substantial additional funding to support its ongoing operations and potential commercialization of its product candidates.
How Inozyme Pharma, Inc. (INZY) Makes Money
Business Model
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for rare diseases, particularly those affecting bone health and blood vessel function. The company’s lead product candidate, INZ-701, targets conditions caused by deficiencies in the ENPP1 enzyme, which generates pyrophosphate (PPi) and adenosine. These therapies aim to correct pathologic mineralization and smooth muscle cell overgrowth, which are significant contributors to various debilitating diseases.
Revenue Generation
As of 2024, Inozyme Pharma has not yet generated any revenue from product sales. The company primarily funds its operations through equity offerings, debt financing, and collaborations. Key financial activities include:
- Proceeds from equity offerings, including common stock and pre-funded warrants.
- Loans under a financing agreement with K2 HealthVentures LLC.
- Future potential revenue from the commercialization of INZ-701, pending successful clinical trials and regulatory approvals.
Financial Overview
Inozyme Pharma has experienced significant financial losses as it invests heavily in research and development. The following table summarizes key financial data for the nine months ended September 30, 2024:
| Category | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Research and Development Expense | $60,758 | $36,864 | $23,894 |
| General and Administrative Expense | $16,101 | $15,973 | $128 |
| Total Operating Expenses | $76,859 | $52,837 | $24,022 |
| Net Loss | $(74,950) | $(49,625) | $(25,325) |
Funding and Financing Activities
Inozyme has utilized various financing strategies to support its operations:
- In September 2024, cash and cash equivalents totaled $24,575,000, with short-term investments of $107,033,000, resulting in total liquid assets of $131,608,000.
- For the nine months ended September 30, 2024, the company reported net cash used in operating activities of $(72,719,000), compared to $(52,188,000) in 2023.
- Net cash provided by financing activities amounted to $11,140,000 in 2024, down from $113,453,000 in 2023, reflecting a decrease in equity offerings and long-term debt proceeds.
Debt Obligations
As of September 30, 2024, Inozyme Pharma had an outstanding long-term debt of $42,065,000. The terms of the debt include:
- A variable interest rate of 9.60% as of September 30, 2024.
- Interest-only payments until September 1, 2025, followed by monthly payments of principal and interest.
- Potential conversion of up to $5 million of the loan into shares of common stock at a conversion price of $6.21 per share.
Market Strategy
Inozyme Pharma's strategy involves advancing its clinical trials for INZ-701 and obtaining marketing approvals. The company is focused on:
- Conducting ongoing clinical trials for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
- Potential commercialization of INZ-701, which could provide revenue through product sales.
Investment and Future Outlook
The company anticipates needing substantial additional funding to support its ongoing research and development activities. If successful, the commercialization of INZ-701 could lead to significant revenue generation opportunities in the future. The following table outlines the expected financial position:
| Financial Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $24,575,000 | $34,588,000 |
| Short-term Investments | $107,033,000 | $154,001,000 |
| Total Assets | $143,361,000 | $200,847,000 |
| Accumulated Deficit | $(360,880,000) | $(285,930,000) |
Inozyme Pharma, Inc. (INZY) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Inozyme Pharma, Inc. (INZY) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Inozyme Pharma, Inc. (INZY)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Inozyme Pharma, Inc. (INZY)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.